In collaboration with James Rowe, I am carrying out multi-modal and longitudinal brain imaging studies of early Alzheimer’s disease to evaluate neurophysiological (MEG, EEG) and positron emission tomography (PET) markers of disease and their relationship to cognitive change and fluidic biomarkers.
The studies aim to discover and validate reliable biomarkers for early-phase clinical trials – sensitive to Alzheimer's and linked to the mechanism of disease as mediators of its progression.
